At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 163 enrolled
Drug / intervention
exenatide +1 moredrug
Likely dose
exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
In Brief
A Phase 2 clinical trial evaluating exenatide and placebo for Obesity. Completed, enrolled 163 participants across 16 sites in 2 countries.
Detailed Summary
This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesPuerto Rico, United States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJul 2007
Primary CompletionFeb 2008
TodayJul 2026
First PostedJul 12, 2007
Enrollment StartJun 1, 2007
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.0 years ago
Interventions
exenatidedrug
subcutaneous injection (5mcg or 10mcg), twice a day
placebodrug
subcutaneous injection (equivalent volume to active dose), twice a day